Literature DB >> 10077084

Effects of L-NAME and L-arginine on ischemia-reperfusion injury in rat skeletal muscle.

D G Meldrum1, L L Stephenson, W A Zamboni.   

Abstract

The involvement of nitric oxide in ischemia-reperfusion injury remains controversial and has been reported to be both beneficial and deleterious, depending on the tissue and model used. This study evaluated the effects of the nitric oxide synthase inhibitor N(G)-nitro-L-arginine-methyl ester (L-NAME) and the substrate for nitric oxide synthase, L-arginine on skeletal muscle necrosis in a rat model of ischemia-reperfusion injury. The rectus femoris muscle in male Wistar rats (250 to 500 g) was isolated on its vascular pedicle and subjected to 4 hours of complete arteriovenous occlusion. The animals were divided into five groups: (1) sham-raised control, no ischemia, no treatment (n = 6); (2) 4 hours of ischemia (n = 6); (3) vehicle control, 4 hours of ischemia + saline (n = 6); (4) 4 hours of ischemia + L-arginine infusion (n = 6); and (5) 4 hours of ischemia + L-NAME infusion (n = 6). The infusions (10 mg/kg) were administered into the contralateral femoral vein beginning 5 minutes before reperfusion and during the following 30 to 45 minutes. Upon reperfusion, the muscle was sutured in its anatomic position and all wounds were closed. The percentage of muscle necrosis was assessed after 24 hours of reperfusion by serial transections, nitroblue tetrazolium staining, digital photography, and computerized planimetry. Sham (group 1) animals sustained baseline necrosis of 11.9 +/- 3.0 (percentage necrosis +/- SEM). Four hours of ischemia (group 2) significantly increased necrosis to 79.2 +/- 1.4 (p < 0.01). Vehicle control (group 3) had no significant difference in necrosis (81.17 +/- 5.0) versus untreated animals subjected to 4 hours of ischemia (group 2). Animals treated with L-arginine (group 4) had significantly reduced necrosis to 34.6 +/- 7.5 versus untreated (group 2) animals (p < 0.01). Animals infused with L-NAME (group 5) had no significant difference in necrosis (68.2 +/- 6.7) versus untreated (group 2) animals. L-Arginine (nitric oxide donor) significantly decreased the severity of muscle necrosis in this rat model of ischemia-reperfusion injury. L-arginine is known to increase the amount of nitric oxide through the action of nitric oxide synthase, whereas L-NAME, known to inhibit nitric oxide synthase and decrease nitric oxide production, had comparable results to the untreated 4-hour ischemia group. These results suggest that L-arginine, presumably through nitric oxide mediation, appears beneficial to rat skeletal muscle subjected to ischemia-reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10077084     DOI: 10.1097/00006534-199903000-00025

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  4 in total

1.  Overexpression of endothelial nitric oxide synthase in endothelial cells is protective against ischemia-reperfusion injury in mouse skeletal muscle.

Authors:  Masanori Ozaki; Seinosuke Kawashima; Tetsuaki Hirase; Tomoya Yamashita; Masayuki Namiki; Nobutaka Inoue; Ken-ichi Hirata Ki; Mitsuhiro Yokoyama
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 2.  Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.

Authors:  Ashish Francis; Richard Baynosa
Journal:  Diving Hyperb Med       Date:  2017-06       Impact factor: 0.887

3.  Sympathetic vasoconstrictor antagonism and vasodilatation relieve mechanical allodynia in rats with chronic postischemia pain.

Authors:  Dimitris N Xanthos; Terence J Coderre
Journal:  J Pain       Date:  2008-02-11       Impact factor: 5.820

4.  Effects of dietary creatine supplementation on kidney and striated skeletal muscles of rats submitted to ischemia and reperfusion of hind limbs.

Authors:  Antonio Augusto Moreira Neto; Acácio Francisco Neto; Fernanda Macedo Dos Reis Moreira; Lawani Rigopoulos; Douglas Tsunemi; Marco Antônio Soufen
Journal:  Acta Cir Bras       Date:  2021-04-21       Impact factor: 1.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.